Aclidinium bromide vs Tiotropium bromide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

Aclidinium bromide · Tudorza Pressair

Marketed by Azurity Pharmaceuticals and partners

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Partial signal

NCT00363896 · Phase 3 · completed

The trial randomized 843 participants to double-blind aclidinium or placebo, with trough FEV1 at 12 and 28 weeks, an accepted lung-function endpoint for COPD, as its primary outcome. The registry posts no significance test, but the publication of ACCLAIM/COPD I reports trough FEV1 improvements over placebo of 61 mL and 67 mL at 12 and 28 weeks (both p<0.001).

Reported efficacy

Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. (met)

Result source: NCT03022097

Tiotropium bromide

Marketed by Boehringer Ingelheim

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Partial signal

NCT02172287 · Phase 3 · completed

This 6-month trial randomly assigned 623 patients with COPD to tiotropium, salmeterol or placebo, with double-blind, double-dummy treatment. The two primary measures were trough FEV1 and the Transition Dyspnea Index (TDI). Tiotropium raised trough FEV1 by 0.14 L more than placebo, more than salmeterol did (0.09 L; p<0.01 for tiotropium against salmeterol), and improved the TDI focal score by 1.02 units against placebo (p=0.01). Both primary measures favoured tiotropium, so the result is met. The figures come from the peer-reviewed paper in Chest (2002).

Reported efficacy

Change from baseline in trough Forced expiratory volume in one second (FEV1) response (baseline, up to day 169); Change from baseline in Mahler Transitional Dyspnoea Index (TDI) (baseline, up to day 169): Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. (met)

Result source: NCT02172287

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAclidinium bromideTiotropium bromide
Moderate or severe exacerbations, annualised rate0.4 vs 0.6−0.1 vs placebowk 52 · n 1791NCT019661070.9 vs 1.3−0.4 vs placebo18μg · n 54NCT01663987
1 other result
  • 0.9 vs 1.3 18 μg · n 54 · Phase 4 · secondary NCT01662986
Trough FEV1, change0.1 vs -0.1+0.2 vs placebo400/12 μg · wk 24 · n 262NCT03022097
25 other results
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg Bid · wk 24 · n 269 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 400/12 μg · wk 24 · n 335 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 1.2 vs 1.2 200 μg once-daily · wk 28 · n 594 · Phase 3 · primary NCT00358436
  • 1.2 vs 1.2 200 μg once-daily · wk 12 · n 594 · Phase 3 · primary NCT00358436
  • 0.1 vs -0.0 400µg · wk 12 · n 190 · Phase 3 · primary NCT00891462
  • 0.1 vs -0.0 400 μg · wk 12 · n 177 · Phase 3 · primary NCT01045161
  • 0.1 vs -0.0 400 μg Bid · wk 12 · n 269 · Phase 3 · primary NCT01001494
  • 0.0 vs -0.1 200 μg Bid · wk 24 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 200µg · wk 12 · n 184 · Phase 3 · primary NCT00891462
  • 0.0 vs -0.0 200 μg · wk 12 · n 182 · Phase 3 · primary NCT01045161
  • 0.0 vs -0.0 200 μg Bid · wk 12 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs 0.1 400/12 μg · wk 24 · n 314 · Phase 3 · primary NCT02796677
  • 0.0 vs -0.1 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • 0.0 vs -0.1 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • 0.1 vs -0.0 wk 6 · n 86 · Phase 3 · secondary NCT00500318
  • 0.1 vs -0.0 400 μg bid · wk 3 · n 30 · Phase 4 · secondary NCT02153489
  • 0.1 vs -0.0 400 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 200 μg Bid · wk 1 · n 72 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 100 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
0.1 vs 0.1vs AB400/12 μg · wk 24 · n 314NCT02796677
42 other results
  • 0.2 vs -0.1 18μg · wk 12 · n 30 · Phase 4 · primary NCT01663987
  • 0.2 vs 0.1 18 μg · wk 12 · n 30 · Phase 4 · primary NCT01662986
  • 0.1 vs 0.1 10 μg · wk 3 · n 30 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 40 μg · wk 3 · n 31 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 20 μg · wk 3 · n 32 · Phase 2 · primary NCT03118765
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 wk 12 · n 152 · Phase 4 · primary NCT00359788
  • 0.1 vs -0.0 200 mcg · wk 18 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 12 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 8 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 4 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 2 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 1 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 18 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 12 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 8 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 4 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 2 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 1 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 18 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 12 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 8 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 4 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 2 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 1 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.2 vs 0.0 18μg · wk 12 · n 60 · Phase 4 · secondary NCT01663987
  • 0.2 vs 0.0 18 μg · wk 12 · n 60 · Phase 4 · secondary NCT01662986
  • 0.1 vs 0.0 200 mcg · wk 0.71 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 200 mcg · wk 0.43 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.71 · n 56 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.43 · n 56 · Phase 2 · secondary NCT00528996
  • 0.0 vs 0.0 50 mcg · wk 0.71 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 50 mcg · wk 0.43 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 wk 6 · n 152 · Phase 4 · secondary NCT00359788
SGRQ total, change-3.6 vs -1.9−1.8 vs placebo400/12 μg · wk 52 · n 335NCT01572792
7 other results
  • -5.5 vs -1.9 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • -7.6 vs -4.7 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • -6.6 vs -2.2 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
-4.1 vs -2.0−2.1 vs placebowk 12 · n 315NCT00496470
TDI focal score2.9 vs 2.1+0.8 vs placebo400/12 μg · wk 24 · n 262NCT03022097
5 other results
  • 2.6 vs 2.1 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • 2.0 vs 0.6 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
—Not posted · NCT02172287

Moderate or severe exacerbations, annualised rate

Aclidinium bromide
0.4 vs 0.6−0.1 vs placebowk 52 · n 1791NCT01966107
Tiotropium bromide
0.9 vs 1.3−0.4 vs placebo18μg · n 54NCT01663987
1 other result
  • 0.9 vs 1.3 18 μg · n 54 · Phase 4 · secondary NCT01662986

Trough FEV1, change

Aclidinium bromide
0.1 vs -0.1+0.2 vs placebo400/12 μg · wk 24 · n 262NCT03022097
25 other results
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg Bid · wk 24 · n 269 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 400/12 μg · wk 24 · n 335 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 1.2 vs 1.2 200 μg once-daily · wk 28 · n 594 · Phase 3 · primary NCT00358436
  • 1.2 vs 1.2 200 μg once-daily · wk 12 · n 594 · Phase 3 · primary NCT00358436
  • 0.1 vs -0.0 400µg · wk 12 · n 190 · Phase 3 · primary NCT00891462
  • 0.1 vs -0.0 400 μg · wk 12 · n 177 · Phase 3 · primary NCT01045161
  • 0.1 vs -0.0 400 μg Bid · wk 12 · n 269 · Phase 3 · primary NCT01001494
  • 0.0 vs -0.1 200 μg Bid · wk 24 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 200µg · wk 12 · n 184 · Phase 3 · primary NCT00891462
  • 0.0 vs -0.0 200 μg · wk 12 · n 182 · Phase 3 · primary NCT01045161
  • 0.0 vs -0.0 200 μg Bid · wk 12 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs 0.1 400/12 μg · wk 24 · n 314 · Phase 3 · primary NCT02796677
  • 0.0 vs -0.1 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • 0.0 vs -0.1 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • 0.1 vs -0.0 wk 6 · n 86 · Phase 3 · secondary NCT00500318
  • 0.1 vs -0.0 400 μg bid · wk 3 · n 30 · Phase 4 · secondary NCT02153489
  • 0.1 vs -0.0 400 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 200 μg Bid · wk 1 · n 72 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 100 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
Tiotropium bromide
0.1 vs 0.1vs AB400/12 μg · wk 24 · n 314NCT02796677
42 other results
  • 0.2 vs -0.1 18μg · wk 12 · n 30 · Phase 4 · primary NCT01663987
  • 0.2 vs 0.1 18 μg · wk 12 · n 30 · Phase 4 · primary NCT01662986
  • 0.1 vs 0.1 10 μg · wk 3 · n 30 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 40 μg · wk 3 · n 31 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 20 μg · wk 3 · n 32 · Phase 2 · primary NCT03118765
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 wk 12 · n 152 · Phase 4 · primary NCT00359788
  • 0.1 vs -0.0 200 mcg · wk 18 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 12 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 8 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 4 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 2 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 1 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 18 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 12 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 8 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 4 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 2 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 1 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 18 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 12 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 8 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 4 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 2 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 1 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.2 vs 0.0 18μg · wk 12 · n 60 · Phase 4 · secondary NCT01663987
  • 0.2 vs 0.0 18 μg · wk 12 · n 60 · Phase 4 · secondary NCT01662986
  • 0.1 vs 0.0 200 mcg · wk 0.71 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 200 mcg · wk 0.43 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.71 · n 56 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.43 · n 56 · Phase 2 · secondary NCT00528996
  • 0.0 vs 0.0 50 mcg · wk 0.71 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 50 mcg · wk 0.43 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 wk 6 · n 152 · Phase 4 · secondary NCT00359788

SGRQ total, change

Aclidinium bromide
-3.6 vs -1.9−1.8 vs placebo400/12 μg · wk 52 · n 335NCT01572792
7 other results
  • -5.5 vs -1.9 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • -7.6 vs -4.7 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • -6.6 vs -2.2 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
Tiotropium bromide
-4.1 vs -2.0−2.1 vs placebowk 12 · n 315NCT00496470

TDI focal score

Aclidinium bromide
2.9 vs 2.1+0.8 vs placebo400/12 μg · wk 24 · n 262NCT03022097
5 other results
  • 2.6 vs 2.1 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • 2.0 vs 0.6 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
Tiotropium bromide
—Not posted · NCT02172287
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety

Coverage. Aclidinium bromide: 13 of 13 rows · Tiotropium bromide: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAclidinium bromide
Rows use multiple source trials
Tiotropium bromide
Rows use multiple source trials
FEV1 AUC0-12h
absolute change · L
0.236 vs 0.015 placebo L @ 2.142857142857143wk400 μg Bida,b,c
NCT00868231 · Phase 2 · registry result, not featured evidence
0.23 vs 0.08 placebo L @ 3wk10 μgd,a,b,c
NCT03118765 · Phase 2 · registry result, not featured evidence
show 2 more doses
0.15 vs 0.08 placebo L @ 3wk40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0.17 vs 0.08 placebo L @ 3wk20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
FEV1 AUC0-3h
absolute change · L
0.237 vs 0.162 AB L @ 24wk400/12 μge,a,b
NCT02796677 · Phase 3 · registry result, not featured evidence
0.16 vs -0.06 placebo L @ 24wke,a,b
NCT00523991 · Phase 4 · registry result, not featured evidence
1 other source trial
0.237 vs 0.162 AB L @ 24wk400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
FEV1 Change 1h
absolute change · L
0.156 vs -0.05 placebo L @ 24wk400 μgd,a,b
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 1 more dose
0.248 vs -0.05 placebo L @ 24wk400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.253 vs 0.169 AB L @ 24wk400/12 μga,b
NCT02796677 · Phase 3 · registry result, not featured evidence
FEV1 Peak
absolute change · L
0.225 vs 0.008 placebo L @ 24wk400 μgd,e,a,b
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 1 more dose
0.324 vs 0.008 placebo L @ 24wk400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.26 vs 0.02 placebo L @ 24wke,a,b
NCT00523991 · Phase 4 · registry result, not featured evidence
3 other source trials
0.216 vs 0.051 placebo L @ 24wk100 mcg
NCT00528996 · Phase 2 · registry result, not featured evidence
0.216 vs 0.051 placebo L @ 24wk200 mcg
NCT00528996 · Phase 2 · registry result, not featured evidence
0.207 vs 0.051 placebo L @ 24wk50 mcg
NCT00528996 · Phase 2 · registry result, not featured evidence
FEV1 Peak
absolute change · L
No placebo or comparator arm
0.172 L @ 52wk400 μgd,f,a,g
NCT01045161 · Phase 3
show 1 more dose
0.176 L @ 52wk200 μg to 400 μg
NCT01045161 · Phase 3
0.264 L @ 4wk5 mcgd,f,a,g
NCT01040403 · Phase 2 · registry result, not featured evidence
show 7 more doses
0.267 L @ 4wk10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
0.412 L @ 4wktiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.379 L @ 4wktiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.399 L @ 4wktiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.355 L @ 4wktiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.374 L @ 4wktiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.353 L @ 4wktiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
FEV1 Trough
absolute value · L
1.428 vs 1.366 placebo L @ 12wk200 μg Once-dailye,a,b
NCT00363896 · Phase 3 · monotherapy
1.225 vs 1.119 Combivent (Ipratropium/Albuterol) L @ 12wke,a,b
NCT00359788 · Phase 4 · registry result, not featured evidence
FEV1 Trough
absolute change · L
No placebo or comparator arm
0.048 L @ 52wk400 μgd,a,b,h
NCT01045161 · Phase 3
show 1 more dose
0.029 L @ 52wk200 μg to 400 μg
NCT01045161 · Phase 3
1.285 L @ 120wk5 mcgd,a,b,h
NCT01126437 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.295 L @ 120wk18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
1.258 L @ 120wk2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
SGRQ
responder rate · % of participants
Number of responders -Yes
48.1% (n=270) vs 49.1% (n=383) AB @ 24wk*400/12 μga,b
Number of responders -Yes
NCT02796677 · Phase 3 · registry result, not featured evidence · converted to % from 130 Participants as posted
48.1% (n=270) vs 49.1% (n=383) AB @ 24wk*400/12 μga,b
Number of responders -Yes
NCT02796677 · Phase 3 · registry result, not featured evidence · converted to % from 130 Participants as posted
Time to First Exacerbation
time to event · months
NA vs NA placebo months @ 52wk200 μg Once-dailye,a,i
NCT00363896 · Phase 3 · monotherapy
0.1 vs 0.33 TIO months*50/250 µg BIDd,e,a,i
NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 3 days as posted
show 5 more doses
0 vs 0 TIO months*50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 0 days as posted
0.16 vs 0.33 TIO months*50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 5 days as posted
0 vs 0 TIO months*50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 0 days as posted
0.07 vs 0.33 TIO months*18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 2 days as posted
0.03 vs 0 TIO months*18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 1 days as posted
Dropout rate
14.2%200 μg Once-dailyj
NCT00363896 · Phase 3 · monotherapy
show 34 more results
25.7%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
7.1%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.9%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—400 μg Bid
NCT01120093 · Phase 2
—200 μg Bid
NCT01120093 · Phase 2
—100 μg Bid
NCT01120093 · Phase 2
12.6%400µg
NCT00891462 · Phase 3
17.8%200µg
NCT00891462 · Phase 3
—400 μg
NCT01045161 · Phase 3
—400 μg
NCT01045161 · Phase 3
—200 μg
NCT01045161 · Phase 3
—200 μg to 400 μg
NCT01045161 · Phase 3
6.3%400 μg Bid
NCT01001494 · Phase 3
8.7%200 μg Bid
NCT01001494 · Phase 3
44.3%
NCT01966107 · Phase 4
4.4%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
—400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
19.5%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
18.3%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
19.5%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
18.3%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
8.8%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
10.5%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
—400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
2.9%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
44.7%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
42.6%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
5.8%
NCT00500318 · Phase 3 · registry result, not featured evidence
—400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
10.3%50/250 µg BIDk
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
—50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
—18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
15%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
33.3%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
—50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT00523991 · Phase 4 · registry result, not featured evidence
7.9%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
13.3%
NCT00359788 · Phase 4 · registry result, not featured evidence
—
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
0%18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
23.2%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
23%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
23.4%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
—150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
13.3%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
16.1%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
6.3%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
3.8%200 μg Once-dailyj
NCT00363896 · Phase 3 · monotherapy
show 34 more results
4.8%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
1.5%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.1%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—400 μg Bid
NCT01120093 · Phase 2
—200 μg Bid
NCT01120093 · Phase 2
—100 μg Bid
NCT01120093 · Phase 2
3.7%400µg
NCT00891462 · Phase 3
4.3%200µg
NCT00891462 · Phase 3
—400 μg
NCT01045161 · Phase 3
—400 μg
NCT01045161 · Phase 3
—200 μg
NCT01045161 · Phase 3
—200 μg to 400 μg
NCT01045161 · Phase 3
1.5%400 μg Bid
NCT01001494 · Phase 3
2.9%200 μg Bid
NCT01001494 · Phase 3
—
NCT01966107 · Phase 4
1.5%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
—400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
6.2%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.5%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.2%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
6.5%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
3.1%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
2.6%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
—400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
1.8%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
6.8%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
7.1%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
3.5%
NCT00500318 · Phase 3 · registry result, not featured evidence
—400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
6.4%50/250 µg BIDk
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
—50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
—18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
5%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
10.3%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
—50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT00523991 · Phase 4 · registry result, not featured evidence
2.4%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
—
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
10.6%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
11.1%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
10.5%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
—150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
3.3%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
3.2%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
3.1%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
1.1%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
8%200 μg Once-dailyj
NCT00363896 · Phase 3 · monotherapy
show 34 more results
10.3%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
7.9%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.2%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.4%400 μg Bid
NCT01120093 · Phase 2
1.4%200 μg Bid
NCT01120093 · Phase 2
0%100 μg Bid
NCT01120093 · Phase 2
3.2%400µg
NCT00891462 · Phase 3
4.3%200µg
NCT00891462 · Phase 3
4.5%400 μg
NCT01045161 · Phase 3
9.5%400 μg
NCT01045161 · Phase 3
6%200 μg
NCT01045161 · Phase 3
13%200 μg to 400 μg
NCT01045161 · Phase 3
5.6%400 μg Bid
NCT01001494 · Phase 3
4.3%200 μg Bid
NCT01001494 · Phase 3
22.8%
NCT01966107 · Phase 4
1.5%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
0%400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
7.3%400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
7.7%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.9%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
5.7%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
5.4%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
6%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
4.7%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
0%400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
1.8%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
10%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
9.3%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
12.3%400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
15.2%400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
14%200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
15.9%200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
2.3%
NCT00500318 · Phase 3 · registry result, not featured evidence
0%400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
—50/250 µg BIDk
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
5.9%50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
8.8%50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
10.7%18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
37.5%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
25.6%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
0%50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
3.8%50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
4.2%
NCT00523991 · Phase 4 · registry result, not featured evidence
3%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
0%
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
7.3%400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
32.9%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
33.9%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
33.8%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
0%150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
0%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
2%5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
1.4%18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
1.4%1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
3.7%5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
1.8%10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
0%tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
2.7%tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.4%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
200 μg Once-dailyj
nasopharyngitis 16.3% (placebo 14.4%)
headache 11.3% (placebo 12.5%)
back pain 4.8% (placebo 4.6%)
NCT00363896 · Phase 3 · monotherapy
show 34 more results
200 μg once-daily
headache 14.2% (placebo 12.7%)
nasopharyngitis 12.7% (placebo 11.3%)
upper respiratory tract infection 10.8% (placebo 9.8%)
NCT00358436 · Phase 3 · monotherapy
400 μg
upper respiratory tract infection 9.4% (placebo 8.9%)
chronic obstructive pulmonary disease 7.9% (placebo 13%)
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
upper respiratory tract infection 11.8% (placebo 8.9%)
chronic obstructive pulmonary disease 9.5% (placebo 13%)
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400 μg Bid
headache 6.8% (placebo 1.3%)
NCT01120093 · Phase 2
200 μg Bid
headache 5.5% (placebo 1.3%)
NCT01120093 · Phase 2
100 μg Bid
headache 5.5% (placebo 1.3%)
NCT01120093 · Phase 2
400µg
chronic obstructive pulmonary disease 7.4% (placebo 12.4%)
NCT00891462 · Phase 3
200µg
chronic obstructive pulmonary disease 9.2% (placebo 12.4%)
NCT00891462 · Phase 3
400 μg
copd exacerbation 13% (placebo 11.5%)
upper respiratory tract infection 1.7% (placebo 0.5%)
nasopharyngitis 1.1% (placebo 0%)
NCT01045161 · Phase 3
400 μg
copd exacerbation 27.9% (placebo 11.5%)
upper respiratory tract infection 5.4% (placebo 0.5%)
nasopharyngitis 4.1% (placebo 0%)
NCT01045161 · Phase 3
200 μg
copd exacerbation 8.7% (placebo 11.5%)
upper respiratory tract infection 1.6% (placebo 0.5%)
nasopharyngitis 1.1% (placebo 0%)
NCT01045161 · Phase 3
200 μg to 400 μg
copd exacerbation 22.7% (placebo 11.5%)
nasopharyngitis 5.8% (placebo 0%)
upper respiratory tract infection 5.8% (placebo 0.5%)
NCT01045161 · Phase 3
400 μg Bid
chronic obstructivce pulmonary disease 14.1% (placebo 20.5%)
headache 12.3% (placebo 8.1%)
nasopharyngitis 11.2% (placebo 8.4%)
NCT01001494 · Phase 3
200 μg Bid
chronic obstructivce pulmonary disease 15.9% (placebo 20.5%)
nasopharyngitis 11.6% (placebo 8.4%)
headache 10.8% (placebo 8.1%)
NCT01001494 · Phase 3
urinary tract infection 5% (placebo 4.7%)
upper respiratory tract infection 4.8% (placebo 5.6%)
viral upper respiratory tract infection 4.4% (placebo 3.7%)
NCT01966107 · Phase 4
400 μg
headache 5.2% (placebo 9.7%)
nasopharyngitis 3% (placebo 6.7%)
NCT02375724 · Phase 4 · registry result, not featured evidence
400 μg bid
erythema 10% (placebo 0%)
NCT02153489 · Phase 4 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary 15.6%
nasopharyngitis 11.5%
headache 5.1%
NCT02796677 · Phase 3 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary disease 20.3% (placebo 15.8%)
urinary tract infection 8.2% (placebo 5.5%)
nasopharyngitis 7.7% (placebo 4.8%)
NCT01572792 · Phase 3 · registry result, not featured evidence
400/6 μg
chronic obstructive pulmonary disease 22.1% (placebo 15.8%)
nasopharyngitis 6.9% (placebo 4.8%)
urinary tract infection 6.4% (placebo 5.5%)
NCT01572792 · Phase 3 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary disease 15.2% (placebo 17.5%)
cough 5.1% (placebo 3.6%)
nasopharyngitis 4.8% (placebo 3.6%)
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
400/6 μg
chronic obstructive pulmonary disease 14.7% (placebo 17.5%)
nasopharyngitis 5.1% (placebo 3.6%)
cough 3.9% (placebo 3.6%)
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
chronic obstructive pulmonary disease 8.6% (placebo 11.9%)
nasopharyngitis 7.8% (placebo 7.2%)
headache 7.5% (placebo 8.2%)
NCT01462942 · Phase 3 · registry result, not featured evidence
400/6 μg
chronic obstructive pulmonary disease 9.4% (placebo 11.9%)
nasopharyngitis 7.9% (placebo 7.2%)
headache 7.1% (placebo 8.2%)
NCT01462942 · Phase 3 · registry result, not featured evidence
400 μg BID
nasopharyngitis 6.3% (placebo 3.7%)
NCT01471171 · Phase 3 · registry result, not featured evidence
400 µg BID
nasopharyngitis 6.4% (placebo 2.4%)
headache 3.5% (placebo 4.7%)
NCT01462929 · Phase 3 · registry result, not featured evidence
400µg
chronic obstructive pulmonary disease 19.9%
NCT01044459 · Phase 3 · registry result, not featured evidence
200µg
chronic obstructive pulmonary disease 19.3%
NCT01044459 · Phase 3 · registry result, not featured evidence
400 μg
chronic obstructive pulmonary disorder 22.6%
nasopharyngitis 9.4%
urinary tract infection 7.5%
NCT00970268 · Phase 3 · registry result, not featured evidence
400 μg
chronic obstructive pulmonary disorder 30.4%
contusion 10.9%
cough 8.7%
NCT00970268 · Phase 3 · registry result, not featured evidence
200 μg
chronic obstructive pulmonary disorder 24.7%
nasopharyngitis 8.6%
back pain 7.5%
NCT00970268 · Phase 3 · registry result, not featured evidence
200 μg
chronic obstructive pulmonary disorder 36.4%
sinusitis 11.4%
upper respiratory tract infection 11.4%
NCT00970268 · Phase 3 · registry result, not featured evidence
cough 5.8% (placebo 3.2%)
headache 5.8% (placebo 7.4%)
upper respiratory tract infection 5.8% (placebo 2.1%)
NCT00500318 · Phase 3 · registry result, not featured evidence
400 μg Bid
diarrhoea 6.9% (placebo 0%)
chronic obstructive pulmonary disease 0% (placebo 10%)
NCT00868231 · Phase 2 · registry result, not featured evidence
50/250 µg BIDk
nasopharyngitis 18.4%
dysphonia 13.2%
bronchitis 5.1%
NCT01762800 · Phase 4 · registry result, not featured evidence
show 27 more results
50/250 µg BID + 18 µg QD
nasopharyngitis 20.6%
bronchitis 10.3%
dysphonia 8.8%
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
18 µg QD + 50/250 µg BID
nasopharyngitis 26.7%
dysphonia 8%
bronchitis 6.7%
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
18μg
chronic obstructive pulmonary disease 37.5% (placebo 43.6%)
bronchitis 7.5% (placebo 5.1%)
insomnia 5% (placebo 5.1%)
NCT01663987 · Phase 4 · registry result, not featured evidence
18 μg
chronic obstructive pulmonary disease 25.6% (placebo 15.4%)
contusion 7.7% (placebo 0%)
oedema peripheral 7.7% (placebo 0%)
NCT01662986 · Phase 4 · registry result, not featured evidence
50/250 µg BID
dysphonia 5.9%
constipation 2%
dry mouth 2%
NCT01751113 · Phase 4 · registry result, not featured evidence
50/250 µg BID + 18 µg QD
dysphonia 9.6%
nasopharyngitis 5.8%
arthralgia 3.8%
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
nasophayngitis 6.7% (placebo 5%)
chronic obstructive pulmonary disease 4.6% (placebo 9.6%)
NCT00523991 · Phase 4 · registry result, not featured evidence
chronic obstructive pulmonary disease 6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary 15.6%
nasopharyngitis 11.5%
headache 5.1%
NCT02796677 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 32.9%
NCT01126437 · Phase 3 · registry result, not featured evidence
18 mcg
chronic obstructive pulmonary disease 33.9%
NCT01126437 · Phase 3 · registry result, not featured evidence
2.5 mcg
chronic obstructive pulmonary disease 33.8%
NCT01126437 · Phase 3 · registry result, not featured evidence
10 μg
cough 3.3% (placebo 0%)
headache 3.3% (placebo 3%)
urinary tract infection 3.3% (placebo 3%)
NCT03118765 · Phase 2 · registry result, not featured evidence
40 μg
dry mouth 12.9% (placebo 0%)
dizziness 3.2% (placebo 6.1%)
back pain 0% (placebo 3%)
NCT03118765 · Phase 2 · registry result, not featured evidence
20 μg
back pain 6.3% (placebo 3%)
headache 6.3% (placebo 3%)
cough 3.1% (placebo 0%)
NCT03118765 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 9.3% (placebo 4.1%)
dyspnoea 2% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
18 mcg
nasopharyngitis 4.8% (placebo 4.1%)
dyspnoea 2.1% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
2.5 mcg
dyspnoea 1.4% (placebo 9.5%)
nasopharyngitis 1.4% (placebo 4.1%)
NCT01222533 · Phase 2 · registry result, not featured evidence
1.25 mcg
nasopharyngitis 6.1% (placebo 4.1%)
dyspnoea 3.4% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 10.2%
chronic obstructive pulmonary disease 5.6%
NCT01040403 · Phase 2 · registry result, not featured evidence
10 mcg
nasopharyngitis 6.4%
chronic obstructive pulmonary disease 5.5%
NCT01040403 · Phase 2 · registry result, not featured evidence
tiotropium 5 mcg + olodaterol 10 mcg
chronic obstructive pulmonary disease 3.6%
nasopharyngitis 1.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 5 mcg + olodaterol 5 mcg
chronic obstructive pulmonary disease 7.3%
nasopharyngitis 2.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 10 mcg
nasopharyngitis 3.6%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 5 mcg
nasopharyngitis 7.1%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 10 mcg
nasopharyngitis 7.3%
chronic obstructive pulmonary disease 6.4%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 5 mcg
nasopharyngitis 11%
chronic obstructive pulmonary disease 3.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 3 weeks versus 2.142857142857143 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 4 versus Phase 3.
  6. fTrial phases differ: Phase 2 versus Phase 3.
  7. gAssessment timepoints differ: 4 weeks versus 52 weeks.
  8. hAssessment timepoints differ: 120 weeks versus 52 weeks.
  9. iThe assessment timepoint is not available for both results.
  10. jPopulation comparability has not been reviewed for 31 of these studies.
  11. kPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aclidinium bromide

SGRQ 57.3% (n=269) vs 41% (n=271) placebo @ 24wk400 μg Bid
responder rate · % of participants
Yes (% Patients with 4-unit decrease)
NCT01001494 · Phase 3
show 3 more results
48.1% (n=591) vs 39.5% (n=200) placebo @ 52wk200 μg Once-daily
Yes (% Patients with 4-unit decrease)
NCT00363896 · Phase 3 · monotherapy
39% (n=574) vs 32.8% (n=195) placebo @ 52wk200 μg once-daily
Yes (% Patients with 4-unit decrease)
NCT00358436 · Phase 3 · monotherapy
56% (n=275) vs 41% (n=271) placebo @ 24wk200 μg Bid
Yes (% Patients with 4-unit decrease)
NCT01001494 · Phase 3
Time to First Moderate or Severe Exacerbation NA vs NA placebo months @ 52wk200 μg once-daily
time to event · months
NCT00358436 · Phase 3 · monotherapy
TDI Focal 2.9 vs 2.1 placebo score @ 24wk400/12 μg
absolute change · score
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
2.6 vs 2.1 placebo score @ 24wk400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
2.017 vs 0.582 placebo score @ 24wk400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
1.977 vs 0.582 placebo score @ 24wk400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
2.508 vs 1.215 placebo score @ 24wk400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
2.377 vs 1.215 placebo score @ 24wk400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
FEV1 AUC 12-24h 0.086 vs -0.103 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 5 more results
0.032 vs -0.128 placebo L @ 6wk400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
0.174 vs -0.032 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.202 vs -0.06 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.047 vs -0.103 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.044 vs -0.103 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
FEV1 AUC(0-24h 0.133 vs -0.062 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 5 more results
0.065 vs -0.085 placebo L @ 6wk400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
0.226 vs -0.006 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.211 vs -0.024 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.1 vs -0.062 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.088 vs -0.062 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
TDI Focal 56.9% (n=262) vs 45.5% (n=257) placebo @ 24wk400 μg Bid
responder rate · % of participants
Yes (% Patients with a 1-unit decrease)
NCT01001494 · Phase 3
show 1 more result
53.3% (n=270) vs 45.5% (n=257) placebo @ 24wk200 μg Bid
Yes (% Patients with a 1-unit decrease)
NCT01001494 · Phase 3
Exacerbation Hospitalization Rate Annualized 0.07 vs 0.1 placebo count @ 52wk
event rate · count
NCT01966107 · Phase 4
E-RS Total -1.75 vs -0.73 placebo score @ 8wk400 μg
absolute change · score
NCT02375724 · Phase 4 · registry result, not featured evidence
E-RS Cough Sputum Domain -0.54 vs -0.33 placebo score @ 8wk400 μg
absolute change · score
NCT02375724 · Phase 4 · registry result, not featured evidence
LCQ Total 1.18 vs 1.24 placebo score @ 8wk400 μg
absolute change · score
NCT02375724 · Phase 4 · registry result, not featured evidence
FEV1 AUC0-24h 0.0953 vs -0.0429 placebo hours @ 3wk400 μg bid
absolute change · hours
NCT02153489 · Phase 4 · registry result, not featured evidence
FEV1 AUC0-12h 0.1394 vs -0.01 placebo hours @ 3wk400 μg bid
absolute change · hours
NCT02153489 · Phase 4 · registry result, not featured evidence

+ 18 further endpoints in the CSV export.

Tiotropium bromide

EXACT Total 27.83 vs 28.88 TIO score @ 4wk50/250 µg BID
absolute value · score
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
36.92 vs 28.88 TIO score @ 4wk50/250 µg BID + 18 µg QD
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
38.26 vs 28.88 TIO score @ 4wk18 µg QD + 50/250 µg BID
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.35 vs 28.8 TIO score @ 8wk50/250 µg BID
absolute value · score
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
37.58 vs 28.8 TIO score @ 8wk50/250 µg BID + 18 µg QD
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
35.87 vs 28.8 TIO score @ 8wk18 µg QD + 50/250 µg BID
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.63 vs 28.4 TIO score @ 12wk50/250 µg BID
absolute value · score
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
36.16 vs 28.4 TIO score @ 12wk50/250 µg BID + 18 µg QD
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
35.57 vs 28.4 TIO score @ 12wk18 µg QD + 50/250 µg BID
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.33 vs 28.93 TIO score @ 16wk50/250 µg BID
absolute value · score
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
35.92 vs 28.93 TIO score @ 16wk50/250 µg BID + 18 µg QD
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
33.79 vs 28.93 TIO score @ 16wk18 µg QD + 50/250 µg BID
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 26.98 vs 28.66 TIO score @ 20wk50/250 µg BID
absolute value · score
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
34.92 vs 28.66 TIO score @ 20wk50/250 µg BID + 18 µg QD
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
34.03 vs 28.66 TIO score @ 20wk18 µg QD + 50/250 µg BID
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 26.5 vs 28.8 TIO score @ 24wk50/250 µg BID
absolute value · score
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
32.72 vs 28.8 TIO score @ 24wk50/250 µg BID + 18 µg QD
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
33.67 vs 28.8 TIO score @ 24wk18 µg QD + 50/250 µg BID
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.76 vs 7.18 TIO score @ 4wk50/250 µg BID
absolute value · score
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
12.39 vs 7.18 TIO score @ 4wk50/250 µg BID + 18 µg QD
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
13.23 vs 7.18 TIO score @ 4wk18 µg QD + 50/250 µg BID
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.75 vs 6.99 TIO score @ 8wk50/250 µg BID
absolute value · score
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.86 vs 6.99 TIO score @ 8wk50/250 µg BID + 18 µg QD
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
11.11 vs 6.99 TIO score @ 8wk18 µg QD + 50/250 µg BID
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.69 vs 6.7 TIO score @ 12wk50/250 µg BID
absolute value · score
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.79 vs 6.7 TIO score @ 12wk50/250 µg BID + 18 µg QD
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
11.3 vs 6.7 TIO score @ 12wk18 µg QD + 50/250 µg BID
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.23 vs 6.82 TIO score @ 16wk50/250 µg BID
absolute value · score
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.66 vs 6.82 TIO score @ 16wk50/250 µg BID + 18 µg QD
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
10.26 vs 6.82 TIO score @ 16wk18 µg QD + 50/250 µg BID
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.33 vs 6.85 TIO score @ 20wk50/250 µg BID
absolute value · score
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
10.8 vs 6.85 TIO score @ 20wk50/250 µg BID + 18 µg QD
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
9.89 vs 6.85 TIO score @ 20wk18 µg QD + 50/250 µg BID
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 5.99 vs 6.58 TIO score @ 24wk50/250 µg BID
absolute value · score
Week 21-24; n=93, 51, 94, 51
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
9.82 vs 6.58 TIO score @ 24wk50/250 µg BID + 18 µg QD
Week 21-24; n=93, 51, 94, 51
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
9.59 vs 6.58 TIO score @ 24wk18 µg QD + 50/250 µg BID
Week 21-24; n=93, 51, 94, 51
NCT01762800 · Phase 4 · registry result, not featured evidence · combination

+ 104 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · Tiotropium bromide's landscape